重酒石酸卡巴拉汀胶囊联合司来吉兰治疗帕金森病的效果  

Effect of Rivastigmine Hydrogen Tartrat Capsules combined with Selegiline in the treatment of Parkinson′s disease

作　　者：雷源标[1] 雷瑜[2] 欧福勇[1] 易继平[1] LEI Yuanbiao;LEI Yu;OU Fuyong;YI Jiping(Department of Neurology,Chenzhou NO.1 People′s Hospital,Hu′nan Province,Chenzhou423000,China;Department of Quality,Chenzhou NO.1 People′s Hospital,Hu′nan Province,Chenzhou423000,China)

机构地区：[1]湖南省郴州市第一人民医院神经内科,湖南郴州423000 [2]湖南省郴州市第一人民医院质量部,湖南郴州423000

出　　处：《中国医药导报》2020年第23期62-65,69,共5页China Medical Herald

基　　金：湖南省卫生计生委科研计划课题(2016B113)。

摘　　要：目的探讨重酒石酸卡巴拉汀胶囊联合司来吉兰治疗帕金森病的效果。方法选取2016年11月—2019年10月湖南省郴州市第一人民医院收治的帕金森病患者100例,采用随机数字表法分为研究组和对照组,每组50例。对照组予以司来吉兰治疗,研究组在对照组基础上联合重酒石酸卡巴拉汀胶囊治疗,两组均治疗8周。比较两组疗效,WHO生存质量(WHOQOL-BREF)、帕金森病评分量表(UPDRS)、自主神经症状量表(SCOPT-AUT)、蒙特利尔认知评估量表(MoCA)评分,胰岛素样生长因子(IGF-1)、β-淀粉样蛋白1-42(Aβ1-42)水平,患侧及健侧的多巴胺转运体(DAT)活性,记录两组治疗期间不良反应情况。结果治疗8周后,研究组的临床总有效率高于对照组,差异有统计学意义(P<0.05)。两组治疗8周后WHOQOL-BREF、MoCA评分,Aβ1-42、IGF-1水平均较治疗前升高,且研究组高于对照组;UPDRS、SCOPT-AUT评分均较治疗前降低,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗8周后两组患侧、对照组健侧DAT活性较治疗前降低,差异均有统计学意义(均P<0.05),治疗8周后研究组健侧DAT活性与治疗前比较,差异无统计学意义(P>0.05)。治疗8周后研究组患侧、健侧DAT活性均高于对照组,差异均有统计学意义(均P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论重酒石酸卡巴拉汀胶囊联合司来吉兰治疗帕金森病,可迅速改善患者临床症状,改善血清Aβ1-42、IGF-1水平,延缓DAT失活速度,且不增加不良反应发生率,疗效显著。Objective To investigate the effect of Rivastigmine Hydrogen Tartrat Capsules combined with Selegiline in the treatment of Parkinson′s disease.Methods A total of 100 patients with Parkinson′s disease admitted to Chenzhou NO.1 People′s Hospital,Hu′nan Province from November 2016 to October 2019 were selected and divided into the study group and the control group by random number table method,with 50 patients in each group.The control group was treated with Selegiline,and the study group was treated with Rivastigmine Hydrogen Tartrat Capsules on the basis of the control group.Both groups were treated for 8 weeks.The curative effect,the scores of WHO quality of life(WHOQOL-BREF),Parkinson′s disease rating scale(UPDRS)and autonomic nerve symptom scale(SCOPT-AUT),montreal cognitive assessment scale(MoCA),the levels of insulin-like growth factor(IGF-1),β-amyloid protein 1-42(Aβ1-42)and dopamine transporter(DAT)activity activity in the affected side and healthy side were compared between the two groups.The adverse reactions during the treatment in both groups were recorded.Results After 8 weeks of treatment,the total clinical effective rate of the study group was higher than that of the control group,with statistically significant difference(P<0.05).After 8 weeks of treatment,WHOQOL-BREF and MOCA scores,the levels of Aβ1-42 and IGF-1 were all higher in both groups than those before treatment,and the study group was higher than the control group;UPDRS and SCOPT-AUT scores were both lower than those before treatment,and the study group was lower than the control group,with statistically significant differences(P<0.05).After 8 weeks of treatment,the DAT activity in the affected side of both groups and the healthy side of the control group decreased compared with that before treatment,and the differences were statistically significant(all P<0.05).The DAT activity in the healthy side of the study group after 8 weeks of treatment was not significantly different from that before treatment(P>0.05).After 8 weeks of

关 键 词：重酒石酸卡巴拉汀胶囊 司来吉兰 帕金森病 疗效 

分 类 号：R742.5[医药卫生—神经病学与精神病学]